医学
梅德林
科克伦图书馆
随机对照试验
副干酪乳杆菌
嗜热链球菌
乳酸菌
重症监护医学
发酵
内科学
食品科学
化学
政治学
法学
作者
Hania Szajewska,Maciej Kołodziej,Agata Skórka,Małgorzata Pieścik‐Lech
标识
DOI:10.1097/mpg.0000000000003441
摘要
ABSTRACT Objectives: Infant formulas (IF) with postbiotics, defined as inanimate microorganisms and/or their components that confer a health benefit on the host, are available. We systematically updated evidence on the safety and health effects of administering iF with postbiotics (with or without other modifications) compared with standard IF. Methods: The Cochrane Library, MEDLINE, and EMBASE databases were searched to December 2021. Results: Eleven randomized controlled trials were included. Using the Cochrane Risk of Bias Tool 2, for the primary outcomes, 5 trials had an overall high risk of bias, and 6 trials had some concerns of bias. Most data were available on IF fermented with Bifidobacterium breve C50 and Streptococcus thermophilus (BB/ST). These formulas, compared with the standard IF, were safe and well tolerated. Postbiotic formulas with additional modifications (ie, formula fermented with BB/ST & prebiotics, partly fermented formula with BB/ST and prebiotics with or without modified milk fat, partly fermented antiregurgitation formula with BB/ST and prebiotics) were generally safe and well tolerated but did not offer clear benefits replicated in other studies. Only limited data were available on formula fermented with Lactobacillus paracasei CBA L74. Conclusions: IF with postbiotics evaluated so far are safe and well tolerated by infants who cannot be breastfed. No firm conclusion can, however, be reached regarding the clinical effects and benefit of one formula over another. It seems reasonable to discuss with healthcare providers current evidence regarding specific modifications in infant formulas and let them decide whether the expected benefits meet expectations and are worth the cost.
科研通智能强力驱动
Strongly Powered by AbleSci AI